J&J Subpoenaed Today, but FDA Unlikely to Clarify Grey Areas of OffLabel Marketing, says Lehman Analyst Tony Clapsis

Today, J&J was subpoenaed for improper marketing of its schizophrenia drug Risperdal, its epilepsy treatment, Topamax, and its heart drug Natrecor.  Read more from Crain's New York. Offlabel drug marketing has reportedly accounted for a large portion of the $3 billion in "kickback" settlements since 2000.  Despite increased Congressional attention on this issue, any FDA action clarifying the grey area between legitimate prescriptions and questionable marketing practices is unlikely to take shape this year, says Lehman Brother's Tony Clapsis (interview video clips below)

Play Video

Offlabel drug marketing update: an interview with Lehman's analyst Tony Clapsis - Bloomberg

Bloomberg - (BLOOM)

Mar. 12, 2007. 06:38 PM EST

Play Video

Tony Clapsis interview continued- Bloomberg

Bloomberg - (BLOOM)

Mar. 12, 2007. 06:43 PM EST